Celldex Therapeutics Inc (CLDX)

Currency in USD
29.54
+0.60(+2.07%)
Closed·
29.540.00(0.00%)
·
CLDX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
28.9530.14
52 wk Range
14.4031.31
Key Statistics
Prev. Close
28.94
Open
29.06
Day's Range
28.95-30.14
52 wk Range
14.4-31.31
Volume
836.74K
Average Volume (3m)
813.93K
1-Year Change
40%
Book Value / Share
7.93
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CLDX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
55.07
Upside
+86.43%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Celldex Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral

Celldex Therapeutics Inc Company Profile

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

Celldex Therapeutics Inc SWOT Analysis


Barzolvolimab's Promise
Explore barzolvolimab's potential in chronic spontaneous urticaria, with a 41% complete response rate at 150 mg Q4W dose, despite setbacks in eosinophilic esophagitis trials
Market Opportunities
Delve into the significant CSU market, with analysts projecting potential peak sales of $1 billion for barzolvolimab, despite challenges in the competitive landscape
Financial Health
Learn about Celldex's robust financial position, with $673 million in cash and a strong Altman Z-Score of 20.23, providing runway through 2027 for continued development
Analyst Outlook
Discover analyst consensus with a strong buy recommendation and price targets ranging from $30 to $90, suggesting significant potential upside from current levels
Read full SWOT analysis

Compare CLDX to Peers and Sector

Metrics to compare
CLDX
Peers
Sector
Relationship
P/E Ratio
−7.6x−2.7x−0.5x
PEG Ratio
0.13−0.070.00
Price/Book
3.7x3.0x2.6x
Price / LTM Sales
1,272.7x8.4x3.2x
Upside (Analyst Target)
86.2%191.8%51.3%
Fair Value Upside
Unlock7.1%8.9%Unlock

Analyst Ratings

13 Buy
2 Hold
1 Sell
Ratings:
16 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 55.07
(+86.43% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Goldman Sachs
Hold34.00+15.10%30.00MaintainMar 02, 2026
Morgan Stanley
Buy44.00+48.95%43.00MaintainFeb 26, 2026
Stifel
Buy58.00+96.34%-MaintainFeb 25, 2026
Cantor Fitzgerald
Buy67.00+126.81%-MaintainJan 06, 2026
Barclays
Sell24.00-18.75%21.00MaintainDec 17, 2025

Earnings

Latest Release
Feb 25, 2026
EPS / Forecast
-1.22 / -1.01
Revenue / Forecast
100.00K / 1.39M
EPS Revisions
Last 90 days

CLDX Income Statement

People Also Watch

10.61
BHVN
-0.56%
30.39
VRDN
+3.65%
15.840
METC
+2.39%
18.010
EYPT
-1.69%
28.54
HRMY
+0.96%

FAQ

What Is the Celldex Therapeutics (CLDX) Stock Price Today?

The Celldex Therapeutics stock price today is 29.54 USD.

What Stock Exchange Does Celldex Therapeutics Trade On?

Celldex Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Celldex Therapeutics?

The stock symbol for Celldex Therapeutics is "CLDX."

What Is the Celldex Therapeutics Market Cap?

As of today, Celldex Therapeutics market cap is 1.97B USD.

What Is Celldex Therapeutics's Earnings Per Share (TTM)?

The Celldex Therapeutics EPS (TTM) is -3.90.

When Is the Next Celldex Therapeutics Earnings Date?

Celldex Therapeutics will release its next earnings report on Apr 30, 2026.

From a Technical Analysis Perspective, Is CLDX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Celldex Therapeutics Stock Split?

Celldex Therapeutics has split 2 times.

How Many Employees Does Celldex Therapeutics Have?

Celldex Therapeutics has 198 employees.

What is the current trading status of Celldex Therapeutics (CLDX)?

As of Mar 05, 2026, Celldex Therapeutics (CLDX) is trading at a price of 29.54 USD, with a previous close of 28.94 USD. The stock has fluctuated within a day range of 28.95 USD to 30.14 USD, while its 52-week range spans from 14.40 USD to 31.31 USD.

What Is Celldex Therapeutics (CLDX) Price Target According to Analysts?

The average 12-month price target for Celldex Therapeutics is 55.07 USD, with a high estimate of 90 USD and a low estimate of 24 USD. 13 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Strong Buy. The stock has an +86.43% Upside potential.

What Is the CLDX Premarket Price?

CLDX's last pre-market stock price is 28.99 USD. The pre-market share volume is 17,700.00, and the stock has decreased by 0.05, or 0.17%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.